GBG Report

Updated Monthly

December 9, 2022

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

New Opportunities

Recurring Opportunities

December 16, 2022 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers). Click here to register.

Did you miss **BARDA Industry Day** on November 15-16? Read G2G's report here.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (11)		
1.	Research Infrastructure Development; and Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional) (NIH/NIA/ORWH) PAR-23-053 (R61/R33) PAR-23-054 (R33)	These FOAs invite applications that propose to develop novel research infrastructure; and support advanced-stage development and utilization of novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. https://grants.nih.gov/grants/guide/pa-files/PAR-23-053.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-23-054.html (R33)	Up to $500,000 per year, for up to 5 years	Proposal: 7/3/23
2.	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) (NIH/NIA) PAR-23-057	This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. https://grants.nih.gov/grants/guide/pa-files/PAR-23-057.html	Dependent upon proposal, for up to 5 years	Proposal: 3/7/23
3.	NOSI: Advancing the Science of Geriatric Palliative Care (NIH) NOT-AG-22-048	This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-22-048.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING (2)		
4.	NSF/CASIS Collaboration on Tissue Engineering and Mechanobiology on the International Space Station to Benefit Life on Earth (NSF/CASIS) NSF 23-522	The solicitation seeks to increase use of the ISS National Lab for flight research projects in the field of biomedical engineering. Ideal proposals will describe a commercial, civil, or academic project to achieve research or technology development objectives that will directly impact fundamental studies on cellular engineering, tissue engineering, and models of physiological systems. https://www.nsf.gov/pubs/2023/nsf23522/nsf23522.htm	Up to $400,000, for up to 3 years	Proposal: 3/6/23
5.	NSF/CASIS Collaboration on Transport Phenomena Research on the International Space Station (ISS) to Benefit Life on Earth (NSF/CASIS) NSF 23-523	The solicitation seeks to increase use of the ISS National Lab for fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions studies. Ideal proposals will describe a commercial, civil, or academic project to achieve research or technology development objectives that will directly impact areas including (but not limited to): Clean water and energy; Carbon emissions and capture; Manufacturing; Medical devices and pharmaceuticals; Microfluidics and nanofluidics; Disaster prevention and mitigation. https://www.nsf.gov/pubs/2023/nsf23523/nsf23523.htm	Dependent upon proposal and available funding	Proposal: 3/6/23
		BIOMEDICAL RESEARCH (1)		
6.	Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) (NIH/NIBIB/NEI/NIA) PAR-24-022	A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. https://grants.nih.gov/grants/guide/pa-files/PAR-24-022.html	Up to $400,000, for up to 3 years	Proposal: 2/16/23
		CANCER (11)		
7.	NCI Cancer Screening Research Network (CSRN): ACCrual, Enrollment, and Screening Sites; Statistics and Data Management Center; and Coordinating and Communication Center (UG1 Clinical Trial Required) (NIH/NCI) RFA-CA-23-020 RFA-CA-23-021 RFA-CA-23-022	These FOAs support a comprehensive effort to provide infrastructure to develop the CSRN. The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. This Network is designed to take advantage of large and diverse populations receiving routine care in a variety of healthcare settings. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-020.html https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-021.html https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-022.html	Up to $750,000 per year, for up to 4 years (ACCESS) Dependent upon proposal, for up to 4 years (SDMC)/(CCC)	Letter of intent: 1/28/23 Proposal: 2/28/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
8.	Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01/UH2 Clinical Trial Not Allowed) (NIH/NCI) PAR-23-051 (U01) PAR-23-052 (UH2)	These FOAs request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. https://grants.nih.gov/grants/guide/pa-files/PAR-23-051.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-052.html (UH2)	Up to $500,000 per year, for up to 5 years (U01) Up to $275,000, for up to 2 years (UH2)	Letter of intent: 1/17/23 Proposal: 2/17/23
9.	Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (NIH/NCI) PAR-22-256	This FOA intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. https://grants.nih.gov/grants/guide/pa-files/PAR-22-256.html	Up to $500,000 per year, for up to 2 years (UG3) Up to $750,000 per year, for up to 4 years (UH3)	Letter of intent: 1/14/23 Proposal: 2/14/23
10.	Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional (FDA/OC) RFA-FD-23-008	The purpose of this NOFO is to encourage new approaches to support therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-008.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 1/3/23 Proposal: 2/27/23
11.	Innovative Molecular Analysis Technologies (IMAT) Program FOAs (R33/R61 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-23-002 (R61) RFA-CA-23-003 (R33) RFA-CA-23-004 (R61) RFA-CA-23-005 (R33)	The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. These FOAs solicit grant applications proposing exploratory research projects focused on the early-stage development, further development, and validation of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-002.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-003.html (R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-004.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-005.html (R33)	Up to $150,000 per year, for up to 3 years (R61) Up to $300,000 per year, for up to 3 years (R33)	Letter of intent: 2/1/23 Proposal: 3/1/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
12.	NOSI: Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed) (NIH/NHLBI) NOT-HL-22-052	The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-052.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
		CENTRAL NERVOUS SYSTEM (2)		
13.	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01/R21 Clinical Trials Not Allowed) (NIH) PAR-23-046 (R01) PAR-23-047 (R21)	These FOAs encourage research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-047.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Proposal: 2/5/23 (R01) Proposal: 2/16/23 (R21)
		COGNITIVE AND BRAIN HEALTH (12)		
14.	NOSI: The Neural Mechanisms of Multi-Dimensional Emotional and Social Representation (NIH/NIMH) NOT-MH-23-120	This NOSI encourages studies in humans and animals investigating how diverse multi-dimensional emotional and/or social cues are represented across brain circuits that are important for mental health relevant cognitive, social, and affective behavioral functions. The term "multi-dimensional" refers to the consideration of multiple modalities, the effects of complex contexts and development, and/or dynamic processes that unfold over a variety of temporal scales. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-120.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/25
		CORONAVIRUS (1)		
15.	Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Not Allowed (HHS/FDA) RFA-FD-23-009	This FOA aims to fund COVID research that will strengthen and advance research in minority health and healthy equity, increase understanding of health disparities, and provide future direction for research that will contribute to regulatory decision making. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-009.html	Up to $500,000, for one year	Proposal: 1/16/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIAGNOSTICS (1)		
16.	ITAP Multiplex Point-of-Care (POC) Diagnostic Tests (POCTRN)	NIBIB is mobilizing and expanding the focus of the RADx Independent Test Assessment Program (ITAP) to increase availability of high-quality, accurate, and reliable COVID-Flu A/B POC tests. NIBIB plans to provide support required to accelerate test validation and regulatory review of molecular and antigen-based POC tests. These efforts will facilitate rapid production and commercialization of COVID-Flu A/B POC tests in the US. https://www.poctrn.org/itap-multiplex-poc-diagnostic-tests	Dependent upon proposal and contract	Proposal: 12/16/22
		DOWN SYNDROME (1)		
17.	Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed) (NIH) PAR-23-067	This FOA encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. https://grants.nih.gov/grants/guide/pa-files/PAR-23-067.html	Up to $275,000, for up to 2 years	Proposal: 3/20/23
		EMERGENCY CARE (1)		
18.	Shipboard Emergency Response (DoD/Navy) N00014-23-S-C004	ONR is interested in receiving proposals that are specifically aimed at gaining an improved fundamental understanding of the physiological/cognitive stressors associated with and/or unique to shipboard damage control; fundamental and limited applied development of technologies/interventions that improve efficiency of shipboard damage control activities; fundamental and limited applied development of technologies/interventions that improve survivability of sailors engaged in shipboard damage control activities and ultimately ship recoverability following the sustainment of damage. https://www.nre.navy.mil/work-with-us/funding-opportunities/shipboard-emergency-response	Up to $300,000 per year, for up to 2 years	White paper: 12/5/22 Proposal: 2/1/23
		ENVIRONMENTAL HEALTH (1)		
19.	Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional) (NIH/NIEHS) RFA-ES-22-010	The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance understanding of the relationships among environmental exposures, human biology, and disease. The EHS CC supports community engagement and translational research as key approaches to improving public health. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-010.html	Up to $850,000 per year, for up to 4 years	Letter of intent: 3/19/23 Proposal: 4/19/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		EPILEPSY (4)		
20.	Pre-Announcement: FY23 Epilepsy Research Program (DoD/CDMRP)	Applications submitted to the FY23 ERP should address one or more of the following Focus Areas: Markers and Mechanisms; Epidemiology; Longitudinal Studies; Innovative Research. Four awards will be offered: Leveraging Research Award; Idea Development Award; Research Partnership Award; Virtual Post-Traumatic Epilepsy Research Center Faculty Award. https://cdmrp.health.mil/pubs/press/2023/23erppreann	Up to $1.2 million, for up to 3 years Dependent upon award mechanism	TBD
		GENOMICS (1)		
21.	Testing Centers for Development of Somatic Cell Genome Editing in Model Organisms (U42) (Clinical Trials Not Allowed) (NIH/ORIP) PAR-23-038	This FOA supports Testing Centers for Somatic Cell Genome Editing in several model organisms. Each center will provide resources and testing services, to the growing community developing new genome editing technologies and conducting preclinical testing based upon these technologies, for therapeutics of human diseases. The testing centers will work with NIH funded investigators to assess the efficacy and safety of in vivo genome editing and delivery technologies, determine genome editing thresholds for specific diseases associated with minimal off-target effects, and ascertain feasibility parameters in a model system. https://grants.nih.gov/grants/guide/pa-files/PAR-23-038.html	Up to $850,000 per year, for up to 5 years Dependent upon type of center	Proposal: 2/1/23
		HEALTH IT (5)		
22.	NIDDK Information Network Coordinating Unit: dkNET-CU (U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-017	dkNET supports the NIDDK community's needs in data science by providing an information portal that connects users to data, analytical tools, and other biomedical research resources. Additionally, dkNET supports researchers by providing a hub for data-driven hypothesis generation; a suite of tools that assist users in FAIR practice, and in improving rigor and reproducibility in research; and a variety of programs to enhance community engagement and workforce development. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-017.html	Dependent upon proposal, for up to 5 years	Letter of intent: 2/28/23 Proposal: 3/31/23
23.	Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) (NIH Common Fund) RFA-RM-23-003	This FOA announces the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-003.html	Up to $200,000, for up to 1 year	Proposal: 2/3/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT		
24.	Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) (NIH/NHLBI) PAR-23-036	The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. https://grants.nih.gov/grants/guide/pa-files/PAR-23-036.html	Up to $75,000 per year, for up to 2 years	Proposal: 2/28/23
25.	Integrative Computational Tools for Systems Biology Research (DoE) DE-FOA-0002878	BSSD solicits applications that propose innovative computational solutions that can integrate large, disparate data types from multiple and varied sources, and/or the integration of data to achieve coordinated knowledge or integration of knowledge to decipher relationships of biological systems of relevance to DOE. Novel computational tools and analytical approaches of large-scale, multimodal, and multiscale data that will lead to scalable solutions for omics analysis, data mining, and knowledge extraction from complex data sets are sought. https://www.grants.gov/web/grants/view-opportunity.html?oppId=344733	Up to $1.05 million	Proposal: 3/28/23
26.	Diver Performance Monitoring System (DoD/Army) Army SBIR 23.4 A234-004	Objective: Develop a solution that monitors relevant physiological markers and can alert divers of predetermined thresholds on risk. This solution includes form factor developments, accurate biomarker readings from sensors, durability for fresh, chlorinated, and salt-water environments, and on device computing to activate alerts based on predetermined thresholds. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Up to $150,000, for 3 months (Phase I)	Proposal: 1/31/23
		HIV/AIDS (21)		
27.	NOSI: Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment (NIH/NIDA) NOT-DA-24-002	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
28.	Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 – CT Not Allowed) (NIH/NIDA) RFA-DA-24-002	This FOA intends to support exploratory studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis in the context of SUDs. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-002.html	Up to $350,000 per year, for up to 2 years (R61) Up to $500,000 per year, for up to 3 years (R33)	Letter of intent: 2/23/23 Proposal: 3/23/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
29.	NOSI: Promoting Research Opportunities on HIV/AIDS in NIAMS (NIH/NIAMS) NOT-AR-23-004	NIAMS would like to promote observational, translational, and basic/pre-clinical research focusing on how the presence or treatment of HIV/AIDS impacts systemic rheumatic, musculoskeletal and skin disease progression and pathogenesis with a focus on utilization of existing HIV cohorts and repositories. NIAMS is interested in supporting studies focused on, but not limited to: delineating the impact of viral or host factors or interaction of these two factors, or anti-retroviral therapy (ART) in people living with HIV (PLWH) on accelerating or worsening or early-onset of comorbidities; studying the prevalence and risk assessment and management of HIV/AIDS-associated comorbidities in PLWH; identifying etiological targets or biomarkers along with mechanistic action for diagnosis or preclinical candidate therapeutic evaluation/development. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-23-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
30.	Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed) (NIH/NICHD/NIMH) RFA-HD-24-006	This FOA aims to utilize archived HIV/AIDS data and biospecimen collections to generate new research questions and findings related to epidemiology, pathogenesis, treatment, prevention, clinical manifestations, and HIV-associated co-infections in maternal, pediatric, and adolescent populations. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-006.html	Up to $275,000, for up to 2 years	Letter of intent: 2/28/23 Proposal: 3/29/23
31.	NOSI: Research to Address 'Ending the HIV Epidemic' Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV (NIH/NIDA) NOT-DA-23-013	The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the 'Ending the HIV Epidemic in the U.S. (EHE)' initiative. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-013.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/27
		IMMUNOLOGY & INFECTIOUS DISEASE (30)		
32.	Cooperative Centers on Human Immunology (U19 Clinical Trial Optional) (NIH/NIAID) RFA-AI-22-069	The program supports mechanistic and hypothesis-testing studies to discover novel molecules, mechanisms, or regulatory pathways governing function of the human immune system in both healthy and vulnerable populations. Studies of interest include immunity related to prevention or treatment of infectious diseases, immune-mediated pathogenesis/sequelae associated with infectious disease, and/or immune-mediated diseases. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-069.html	Up to $2.5 million per year, for up to 5 years	Letter of intent: 3/7/23 Proposal: 4/7/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
33.	NOSI: Healthcare Associated Infections and Combating Antibiotic Resistant Bacteria Research (AHRQ) NOT-HS-23-003	This NOSI supports innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. Applications studying healthcare delivery that directly benefit patient outcomes, contribute to the understanding of HAIs, and improve healthcare delivery are most suitable for the listed NOFOs. https://grants.nih.gov/grants/guide/notice-files/NOT-HS-23-003.html	Dependent upon proposal and award mechanism	Multiple deadlines; linked grants open through 10/31/23
34.	International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-067	This FOA solicits applications for the ICEMR Program, a multidisciplinary network of Centers that will conduct research in malaria-endemic sites to 1) improve our understanding of malaria pathogenesis, epidemiology, and transmission; and 2) evaluate, optimize, and inform development of interventions to understand, control, eliminate, and eventually eradicate malaria. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-067.html	Up to $800,000 per year, for up to 5 years	Letter of intent: 4/4/23 Proposal: 5/4/23
35.	NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) (NIH/NIAID) PAR-23-065	The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html	Dependent upon proposal, for up to 5 years	Letter of intent: 12/24/22 Proposal: 1/25/23
36.	NOSI: Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics (NIH/NIAID/NIBIB/NCI) NOT-AI-23-001	This NOSI encourages applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections. In addition, the NCI has special interest in developing Point-of-Care testing for HCV diagnosis that will lead to further assessment of the liver damage, stage of fibrosis/cirrhosis and ultimately the risk for liver cancer. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-001.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
37.	NOSI: Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine (NIH/NIAID) NOT-AI-23-007	The proposed research should have clear relevance to the strategic priorities defined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-007.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
38.	NOSI: Complement in Fundamental Immunology (NIH/NIAID) NOT-AI-23-012	The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-012.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
39.	NOSI: Advancing Research for Tickborne Diseases (TBDs) (NIH) NOT-AI-23-013	This NOSI encourages applications to advance Tickborne Disease Research: Improve fundamental knowledge of TBDs; Advance research to improve the diagnosis of TBDs; Accelerate research to improve TBD prevention; Promote research to improve treatment for all forms of TBDs; Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-013.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
40.	Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Neglected Tropical Diseases (CDC/ERA) RFA-GH-23-001	This NOFO intends to expand CDC's network of collaborating institutes for both research with, and technical assistance to, neglected tropical diseases-endemic countries, particularly in sub-Saharan Africa. This NOFO will focus on research synthesis and operational research aimed at controlling and eliminating selected NTDs and other vector-borne parasitic diseases, as well as approaches to integrated activities that cross health sectors. https://www.grants.gov/web/grants/view-opportunity.html?oppId=342978	Up to $1.5 million	Proposal: 3/10/23
		MASS CASUALTY INCIDENTS (1)		
41.	DARPA Triage Challenge (DoD/DARPA) HR001123S0011	The DARPA Triage Challenge seeks to enable medical responders to save lives in MCIs by 1) exploiting stand-off sensors to rapidly and autonomously provide information needed in primary triage, and 2) providing continued monitoring to predict the need for LSIs in secondary triage. The DARPA Triage Challenge will focus on life-threatening conditions that medics are trained to treat, including hemorrhage and airway injuries. https://sam.gov/opp/9f3fdae8285e44aabdeb0a9c3dfd6c17/view	Dependent upon proposal and award mechanism	Abstract: 12/20/22 Proposal: 2/13/23
		MEDICAL COUNTERMEASURES (2)		
42.	Development of Radiation/Nuclear Medical Countermeasures (MCMs) or Biodosimetry Devices (NIH/NIAID) BAA-75N93022R00021	The goal of this BAA is to solicit proposals for (a) the development of medical countermeasures (MCMs) against radiation injury or, (b) biodosimetry approaches targeting radiation-specific biomarker identification and/or device development to predict acute and/or delayed damage to specific organs and tissues beyond dose assessment. https://sam.gov/opp/958f818ff5f44a18be32b4c20cb44a02/view	Dependent upon proposal and award mechanism	Proposal: 2/27/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES		
43.	NIAID/NIH Centers for Medical Countermeasures Against Radiation (CMCR) Program Call for Pilot Project Applications 2023 (NIH/NIAID/CMCRC)	The goals of this FOA are to: 1) develop new techniques and devices to measure radiation exposure in the human body; 2) follow biomarkers of tissue damage and recovery; and 3) further develop existing (e.g. products in clinical use) as well as novel therapies to minimize tissue damage, hasten tissue recovery, restore normal physiological function, and improve survival. https://cmcrcniaid.org/content/instructions	Up to $100,000 per year, for up to 2 years	Proposal: 3/1/23
		MENTAL HEALTH (2)		
44.	Strengthening Resilient Emotions and Nimble Cognition Through Engineering Neuroplasticity (STRENGTHEN) (DoD/DARPA) HR001123S0016	This FOA solicits innovative research proposals in the area of neurobehavioral protective factors and wellbeing to prevent and mitigate the effects of traumatic stress leading to suicidality and behavioral health disorders in warfighters. Proposed research should investigate innovative approaches that enable revolutionary advances in science, devices, or systems. https://sam.gov/opp/cfa6904dfe7a448289ea3ff4b01b7e29/view	Dependent upon proposal and award mechanism	Proposal: 1/23/23
45.	Social Drivers of Mental Illnesses in Low- & Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional) (NIH/NIMH) RFA-MH-23-310	This FOA solicits research that will help to identify and explain the mechanisms by which (i) interventions targeting social drivers of mental illnesses affect the mental health and functioning and (ii) interventions preventing, detecting and treating mental illnesses affect the functioning of children and/or adolescents (ages 5-24 years) living in low- and middle-income countries (LMICs). https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-310.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 1/17/23 Proposal: 2/17/23
		MUSCULOSKELETAL HEALTH (2)		
46.	Ancillary Studies to Ongoing Clinical Projects (R01/R21 Clinical Trial Not Allowed) (NIH/NIAMS) PAR-23-025 (R01) PAR-23-026 (R21)	These FOAs solicit applications that propose to conduct time-sensitive ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, active, ongoing clinical projects (parent projects). The parent project can be an interventional clinical trial, or a clinical study such as an observational study, or a disease-specific repository that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. https://grants.nih.gov/grants/guide/pa-files/PAR-23-025.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html (R21)	Up to $300,000 per year, for up to 4 years (R01) Up to $400,000, for up to 2 years (R21)	Letter of intent: 3/6/23 Proposal: 4/6/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH (3)		
47.	Pre-Announcement: Engagement Award: Capacity Building -- April 2023 Cycle (PCORI)	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2023-cycle	Up to $250,000, for up to 2 years	System opens: 1/18/23 Letter of intent: 4/3/23 Proposal: 7/10/23
48.	Pre-Announcement: Engagement Award: Dissemination Initiative -- April 2023 Cycle (PCORI)	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2023-cycle	Up to $250,000, for up to 2 years	System opens: 1/18/23 Letter of intent: 4/3/23 Proposal: 7/10/23
49.	Pre-Announcement: Engagement Award: Stakeholder Convening Support -- April 2023 Cycle (PCORI)	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2023-cycle	Up to $100,000, for up to 1 year	System opens: 1/18/23 Letter of intent: 4/3/23 Proposal: 7/10/23
		PUBLIC HEALTH (2)		
50.	Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01/R61/R33 Clinical Trial Optional/Required) (NIH) PAR-23-042 (R01) PAR-23-043 (R61/R33)	These FOAs support applications that propose implementation research to reduce the risks of NCDs in the context of cities in LMICs and/or among AI/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. https://grants.nih.gov/grants/guide/pa-files/PAR-23-042.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-043.html (R61/R33)	Dependent upon proposal, for up to 5 years	Letter of intent: 2/9/23 Proposal: 3/9/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		REGENERATIVE MEDICINE (1)		
51.	Opportunities for Advancing Limb Regeneration Research (R01 Clinical Trial Not Allowed) (NIH/NICHD) RFA-HD-24-004	The purpose of this FOA is to promote transformative basic research on limb regeneration using animal models. The primary focus is on gaining insight into the body's own growth regulatory networks and processes that can be manipulated to promote limb regeneration in vertebrates including in mammals that might otherwise lack the capacity for regeneration. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-004.html	Up to $499,999 per year, for up to 5 years	Letter of intent: 6/27/23 Proposal: 7/27/23
		REGULATORY SCIENCE (1)		
52.	FY23 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (FDA) FDABAA-23-00123	This BAA supports research and development to support regulatory science and innovation. Research areas include: Modernize development and evaluation of FDA-regulated products; Strengthen post-market surveillance and labeling of FDA-regulated products; and Invigorate public health preparedness and response of the FDA, patients, and consumers. https://sam.gov/opp/6fd7bbaedd894978871de92ea572e354/view	Dependent upon proposal and award mechanism	White papers: 1/23/23
		SUBSTANCE USE DISORDER (2)		
53.	HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program and Leadership/Data Co-ordinating Center (R01/U01 Clinical Trial Optional) (NIH) RFA-DA-23-059 (R01) RFA-DA-23-060 (U01)	The overall goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to delineate sleep and/or circadian-based predictors of OUD treatment response and outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-059.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-060.html (U01)	Up to $3 million, for up to 4 years (R01) Up to $1.5 million, for up to 4 years (U01)	Letter of intent: 1/10/23 Proposal: 2/10/23
		THERAPEUTICS (4)		
54.	Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed (FDA/CDER) RFA-FD-23-012	The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetylgalactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereochemically-controlled synthesis and biological activity assessment using in vitro and animal models. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-012.html	Up to $1.2 million, for up to 3 years	Letter of intent: 1/20/23 Proposal: 3/22/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
55.	Designing and Performing a Virtual Bioequivalence Trial for Physiologically-Based Pharmacokinetic and other Mechanism-Based Models (U01) Clinical Trial Not Allowed (FDA/CDER) RFA-FD-23-016	The goal of this FOA is to develop a workflow for designing and performing a reliable virtual bioequivalence study by leveraging a physiologically-based pharmacokinetic (PBPK) model, validated for its intended purpose, to detect formulation differences between the reference standard product and a prospective generic drug product. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-016.html	Up to $250,000 per year, for up to 2 years	Letter of intent: 12/16/22 Proposal: 2/15/23
56.	Population Pharmacokinetic Modeling of Systemic Pharmacokinetic Data to Inform Bioequivalence in Regional Lung Exposure (U01) Clinical Trial Not Allowed (FDA/CDER) RFA-FD-23-017	This FOA aims to support research that will use modeling and simulation to investigate the feasibility of assessing formulation differences in regional lung exposure based on systemic PK concentration data to establish BE for OIDPs with different drug and product properties. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-017.html	Up to $250,000 per year, for up to 2 years	Letter of intent: 1/9/23 Proposal: 2/28/23
57.	Evaluation of Oral Modified Release Dosage Forms to Support the Approval of Additional Strengths (U01) Clinical Trial Not Allowed (FDA/CDER) RFA-FD-23-013	The purpose of this project is to determine the critical quality attributes for different release controlling platform technologies and to determine the appropriate factors to scale the formulation for additional strengths. The outcomes of this research are intended to support generic drug development and regulatory decision making. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-013.html	Up to $450,000, for up to 2 years	Letter of intent: 1/7/23 Proposal: 3/15/23
		UROLOGIC RESEARCH (1)		
58.	Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-027	The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-027.html	Up to $250,000 per year, for up to 3 years	Letter of intent: 2/8/23 Proposal: 3/8/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
59.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332	Up to $49 million, per award	White papers accepted on rolling basis until 4/30/26
60.	Air Force Office of Scientific Research Broad Agency Announcement FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996	Dependent upon proposal	Proposals accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
61.	Research Interests of the Air Force Office of Scientific Research FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research. https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
62.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
63.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3c0e11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
64.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppId=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
65.	USSOCOM BAA for Extramural Biomedical Research and Development W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
66.	Army Research Office Broad Agency Announcement for Fundamental Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/72a662246119 42dd9215e60722caaac5/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
67.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-18-S-0005	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462	Dependent upon proposal	Proposals accepted on a rolling basis until 4/29/23 Full proposal required
68.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
69.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
70.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
71.	BARDA Broad Agency Announcement BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics. https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view https://www.medicalcountermeasures.gov/barda/barda-baa	Dependent upon proposal	White papers: 12/15/22
72.	BARDA DRIVe EZ-BAA EZBAA-22-100-SOL-00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #18: Host-Directed Therapeutics; AOI #19: Healing Lungs; AOI #20: DRIVe Forward ; AOI #21: Vaccines on Demand; AOI #22: ReBoot; AOI #23: Host-Based Diagnostics; AOI #24: Repurposing and Advancing Innovations Against Rad/Nuc Threats (REPAIR). https://sam.gov/opp/c24b8eba795743b9a0194a078163d04f/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
73.	Biological Technologies BAA HR001122S0034	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense https://sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 4/20/23
74.	Redefining Possible - 2022 HR001122S0040	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view	Up to $1 million, for up to 18 months	Proposals accepted on a rolling basis until 6/21/23
75.	Defense Sciences Office, Office-wide HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/14/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (2)		
76.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2024
77.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across three interrelated thrust areas derived from the 2019 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand the environment, threats, and vulnerabilities • Control, defeat, disable, and dispose of threats • Safeguard the force and manage consequences https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97f0/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		DEPARTMENT OF ENERGY (1)		
78.	FY2023 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0002844	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=343866	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/23
		NATIONAL SCIENCE FOUNDATION (1)		
79.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click here for project pitch details and for the full list of topics click here. https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to $275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 11/22/22 to 3/1/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY (3)		
80.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N00014-23-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/23
81.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/58eeca6ef84a4d25b41b0edaca42447a/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/23
82.	Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943022S2401	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/31a0cb3fe2fc4777b2f723ebe37a7d59/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 3/21/23